JAGDEV SINGH

Dr. JAGDEV SINGH

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2021 in European Journal of Pediatrics
Verified
Journal Article
Closed access
PDF file
JSJAGDEV SINGH
JAGDEV SINGH
AJAdam Jaffe
Adam Jaffe
ASAndré Schultz
André Schultz
HSHiran Selvadurai
Hiran Selvadurai

1 March 2022 in Paediatric Respiratory Reviews
Verified
Journal Article
Closed access
JSJAGDEV SINGH
JAGDEV SINGH
STSusan Towns
Susan Towns
GJGeshani Jayasuriya
Geshani Jayasuriya
SHSharon Hunt
Sharon Hunt
SSSharon Simonds
Sharon Simonds
DFDominic A. Fitzgerald
Dominic A. Fitzgerald

20 April 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JSJAGDEV SINGH
JAGDEV SINGH
SHSharon Hunt
Sharon Hunt
SSSharon Simonds
Sharon Simonds
CBChristie Boyton
Christie Boyton
AMAnna Middleton
Anna Middleton
HSHiran Selvadurai
Hiran Selvadurai
The impact of evolving treatment regimens, airway clearance strategies, and antibiotic combinations on the incidence and prevalence of respiratory infection in cystic fibrosis (CF) in children and adolescents remains unclear. The incidence, prevalence, and prescription trends from 2002 to 2019 with 18,339 airway samples were analysed. Staphylococcus aureus [− 3.86% (95% CI − 5.28–2.43)] showed the largest annual decline in incidence, followed by Haemophilus influenzae [− 3.46% (95% CI − 4.95–1.96)] and Pseudomonas aeruginosa [− 2.80%95% CI (− 4.26–1.34)]. Non-tuberculous mycobacteria and Burkholderia cepacia showed a non-significant increase in incidence. A similar pattern of change in prevalence was observed. No change in trend was observed in infants < 2 years of age. The mean age of the first isolation of S. aureus (p < 0.001), P. aeruginosa (p < 0.001), H. influenza (p < 0.001), Serratia marcescens (p = 0.006) and Aspergillus fumigatus (p = 0.02) have increased. Nebulised amikacin (+ 3.09 ± 2.24 prescription/year, p = 0.003) and colistin (+ 1.95 ± 0.3 prescriptions/year, p = 0.032) were increasingly prescribed, while tobramycin (− 8.46 ± 4.7 prescriptions/year, p < 0.001) showed a decrease in prescription. Dornase alfa and hypertonic saline nebulisation prescription increased by 16.74 ± 4.1 prescriptions/year and 24 ± 4.6 prescriptions/year (p < 0.001). There is a shift in CF among respiratory pathogens and prescriptions which reflects the evolution of cystic fibrosis treatment strategies over time.

9 May 2023 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
JSJAGDEV SINGH
JAGDEV SINGH
DFDominic A Fitzgerald
Dominic A Fitzgerald
AJAdam Jaffe
Adam Jaffe
SHSharon Hunt
Sharon Hunt
JBJeremy J Barr
Jeremy J Barr
HSHiran Selvadurai
Hiran Selvadurai
Introduction: Cystic fibrosis (CF) is a multisystem condition that is complicated by recurrent pulmonary infections requiring aggressive antibiotic treatment. This predisposes the patient to complications such as sensorineural hearing loss, renal impairment, hypersensitivity and the development of antibiotic resistance. Pseudomonas aeruginosa is one of the more common organisms which cause recurrent infections and result in greater morbidity and mortality in people living with CF. Bacteriophages have been identified as a potential alternative or adjunct to antibiotics. We hypothesise that bacteriophage therapy is a safe and well-tolerated treatment in children with CF infected with P. aeruginosa infection in their airways. Methods: This single-arm, open-labelled, non-randomised trial will run for a maximum period of 36 months with up to 10 participants. Adolescents (≥12 years and <18 years of age) who continue to shed P.aeruginosa (within 3 months of enrolment) despite undergoing eradication therapy previously, will be considered for this trial. Non-genetically modified bacteriophages that have demonstrated obligate lytic activity against each of the study participants’ P. aeruginosa strains will be selected and prepared according to a combination of established protocols (isolation, purification, sterility testing and packaging) to achieve close to good manufacturing practice recommendations. The selected bacteriophage will be administered endo-bronchially first under direct vision, followed by two times a day nebulisation for 7 days in addition to standard CF treatment (intravenous antibiotics, physiotherapy to be completed as inpatient for 10–14 days). Safety and tolerability will be defined as the absence of (1) fever above 38.5°C occurring within 1 hour of the administration of the nebulised bacteriophage, (2) a 10% decline in spirometry (forced expiratory volume in 1 s %) measured preadministration and postadministration of the first dose of nebulised bacteriophage. Clinical reviews including repeat sputum cultures and spirometry will be performed at 3, 6, 9 and 12 months following bacteriophage treatment. Ethics and dissemination: Our clinical trial is conducted in accordance with (1) good clinical practice, (2) Australian legislation, (3) National Health and Medical Research Council guidelines for the ethical conduct of research. Trial registration number: Australia and New Zealand Clinical Trial Registry (ACTRN12622000767707).

31 July 2024 in Virus Research
Verified
Journal Article
Open access
JSJAGDEV SINGH
JAGDEV SINGH
SLStephanie Lynch
Stephanie Lynch
JIJonathan Iredell
Jonathan Iredell
HSHiran Selvadurai
Hiran Selvadurai
Pseudomonas aeruginosa is an organism well known for causing significant morbidity and mortality in people living with chronic lung conditions such as cystic fibrosis. We describe the safety, tolerability, and potential efficacy of bronchoscopic and nebulised bacteriophage administration, offering insights into a potential breakthrough for the treatment of chronic infections particularly in children and adolescents. A 12-year-old female (F12) and a 17-year-old male (M17), both diagnosed with cystic fibrosis and chronic P. aeruginosa lung infection, underwent bacteriophage treatment (BT). The administration involved bronchoscopic instillation and subsequent nebulisation. This was performed concurrently with intravenous antibiotics and regular physiotherapy delivered in an in-patient setting for 14 days. Microbiological, clinical, and lung function assessments were conducted to assess this treatment modality. No adverse events (fever, localised reaction, wheeze or bronchospasm) occurred during BT. F12 demonstrated a 4% increase, while M17 showed a 5% improvement in FEV1% from their best FEV1% over the past three years following BT. A 12% (F12) and an 8% (M17) improvement from baseline FEV1% was observed. For F12 P. aeruginosa was not isolated from her sputum despite 12 previous hospitalisations for intravenous antibiotics. Bronchoscopic and nebulised routes of bacteriophage administration were well-tolerated in these two adolescents. This early report underscores the potential of this treatment modality and encourages clinicians and researchers to actively explore this innovative approach.

11 August 2023 in Paediatric Respiratory Reviews
Verified
Journal Article
Closed access
JSJAGDEV SINGH
JAGDEV SINGH
EYEugene Yeoh
Eugene Yeoh
DFDominic A. Fitzgerald
Dominic A. Fitzgerald
HSHiran Selvadurai
Hiran Selvadurai